The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2021 | Myeloma research: the next 10 years
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, shares his views on the next steps for multiple myeloma research, highlighting the need to optimize when therapy is commenced, identify the best combination approaches, incorporate measurable residual disease (MRD), and the potential benefits and optimal use of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
